Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 290.6
(1.18%)
SEK 290.6
(1.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.23 Billion SEK | 26.25% |
| 2022 | 6.05 Billion SEK | 7.31% |
| 2021 | 5.71 Billion SEK | -8.27% |
| 2020 | 6.72 Billion SEK | 4.2% |
| 2019 | 6.01 Billion SEK | 66.81% |
| 2018 | 3.62 Billion SEK | 73.97% |
| 2017 | 2.07 Billion SEK | 33.22% |
| 2016 | 1.58 Billion SEK | 238.78% |
| 2015 | 462.31 Million SEK | -31.11% |
| 2014 | 51.57 Million SEK | 178.76% |
| 2013 | 241.95 Million SEK | 98.45% |
| 2012 | 391.45 Million SEK | 168.0% |
| 2011 | -46.9 Million SEK | -207.77% |
| 2010 | 165.2 Million SEK | 268.94% |
| 2009 | 44.77 Million SEK | 112.99% |
| 2008 | -364.77 Million SEK | -321.65% |
| 2007 | 141.56 Million SEK | -27.12% |
| 2006 | 168.99 Million SEK | 266.2% |
| 2005 | -128.35 Million SEK | -258.34% |
| 2004 | 81.06 Million SEK | 124.35% |
| 2003 | -332.88 Million SEK | -543.24% |
| 2002 | 75.1 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.22 Billion SEK | -14.54% |
| 2024 Q2 | 1.55 Billion SEK | -30.02% |
| 2024 Q3 | 2.96 Billion SEK | 90.55% |
| 2023 Q2 | 1.05 Billion SEK | -51.3% |
| 2023 Q4 | 2.6 Billion SEK | 75.2% |
| 2023 Q3 | 1.48 Billion SEK | 41.2% |
| 2023 Q1 | 2.15 Billion SEK | -12.67% |
| 2023 FY | - SEK | 26.25% |
| 2022 Q3 | 1.27 Billion SEK | 43.92% |
| 2022 Q4 | 2.47 Billion SEK | 93.35% |
| 2022 Q2 | 888 Million SEK | -39.22% |
| 2022 FY | - SEK | 7.31% |
| 2022 Q1 | 1.46 Billion SEK | -28.45% |
| 2021 Q1 | 1.51 Billion SEK | -38.42% |
| 2021 Q4 | 2.04 Billion SEK | 69.88% |
| 2021 Q3 | 1.2 Billion SEK | 25.6% |
| 2021 Q2 | 957 Million SEK | -36.96% |
| 2021 FY | - SEK | -8.27% |
| 2020 Q3 | 965 Million SEK | 9.41% |
| 2020 Q1 | 2.2 Billion SEK | -4.17% |
| 2020 Q2 | 882 Million SEK | -60.0% |
| 2020 FY | - SEK | 4.2% |
| 2020 Q4 | 2.46 Billion SEK | 155.44% |
| 2019 Q3 | 1.13 Billion SEK | 6.59% |
| 2019 Q4 | 2.3 Billion SEK | 103.27% |
| 2019 FY | - SEK | 66.81% |
| 2019 Q1 | 1.53 Billion SEK | 63.59% |
| 2019 Q2 | 1.06 Billion SEK | -30.99% |
| 2018 FY | - SEK | 73.97% |
| 2018 Q3 | 942 Million SEK | -1.98% |
| 2018 Q2 | 961 Million SEK | 23.21% |
| 2018 Q4 | 940.77 Million SEK | -0.13% |
| 2018 Q1 | 780 Million SEK | 25.13% |
| 2017 FY | - SEK | 33.22% |
| 2017 Q4 | 623.37 Million SEK | 14.59% |
| 2017 Q3 | 544 Million SEK | 9.02% |
| 2017 Q2 | 499 Million SEK | 20.24% |
| 2017 Q1 | 415 Million SEK | 95.54% |
| 2016 FY | - SEK | 238.78% |
| 2016 Q3 | 288 Million SEK | -48.29% |
| 2016 Q1 | 510 Million SEK | 434.66% |
| 2016 Q2 | 557 Million SEK | 9.22% |
| 2016 Q4 | 212.23 Million SEK | -26.31% |
| 2015 Q3 | 105 Million SEK | 28.05% |
| 2015 FY | - SEK | -31.11% |
| 2015 Q1 | 181 Million SEK | -52.08% |
| 2015 Q4 | 95.38 Million SEK | -9.16% |
| 2015 Q2 | 82 Million SEK | -54.7% |
| 2014 Q4 | 377.7 Million SEK | 195.77% |
| 2014 FY | - SEK | 178.76% |
| 2014 Q3 | 127.7 Million SEK | 698.13% |
| 2014 Q2 | 16 Million SEK | 104.47% |
| 2014 Q1 | -358 Million SEK | -6116.36% |
| 2013 Q2 | -31.9 Million SEK | -838.24% |
| 2013 Q1 | -3.4 Million SEK | -104.69% |
| 2013 Q4 | -5.75 Million SEK | 78.1% |
| 2013 FY | - SEK | 98.45% |
| 2013 Q3 | -26.3 Million SEK | 17.55% |
| 2012 Q3 | -15.3 Million SEK | 78.08% |
| 2012 Q4 | 72.57 Million SEK | 574.31% |
| 2012 FY | - SEK | 168.0% |
| 2012 Q1 | 310.5 Million SEK | 197.88% |
| 2012 Q2 | -69.8 Million SEK | -122.48% |
| 2011 Q2 | 127.3 Million SEK | 299.84% |
| 2011 Q3 | -54.4 Million SEK | -142.73% |
| 2011 FY | - SEK | -207.77% |
| 2011 Q4 | -317.21 Million SEK | -483.11% |
| 2011 Q1 | -63.7 Million SEK | -176.47% |
| 2010 FY | - SEK | 268.94% |
| 2010 Q1 | 75 Million SEK | -6.22% |
| 2010 Q2 | 74.2 Million SEK | -1.07% |
| 2010 Q4 | 83.3 Million SEK | 2.21% |
| 2010 Q3 | 81.5 Million SEK | 9.84% |
| 2009 Q3 | -6.3 Million SEK | -108.57% |
| 2009 Q1 | 46 Million SEK | 0.0% |
| 2009 Q4 | 79.97 Million SEK | 1369.48% |
| 2009 FY | - SEK | 112.99% |
| 2009 Q2 | 73.5 Million SEK | 59.78% |
| 2008 FY | - SEK | -321.65% |
| 2007 FY | - SEK | -27.12% |
| 2006 FY | - SEK | 266.2% |
| 2005 FY | - SEK | -258.34% |
| 2004 FY | - SEK | 124.35% |
| 2003 FY | - SEK | -543.24% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 52937.631% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 19203.201% |
| BioGaia AB (publ) | 466.19 Million SEK | -1451.728% |
| Enzymatica AB (publ) | -41.12 Million SEK | 17691.557% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 16902.546% |
| Gabather AB (publ) | 37 Thousand SEK | -19551251.351% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | 49077.657% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 26933.007% |
| Nanexa AB (publ) | -70.79 Million SEK | 10318.813% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | 58722.366% |
| ODI Pharma AB | 1.36 Million SEK | -528947.517% |
| Orexo AB (publ) | -22 Million SEK | 32981.818% |
| Probi AB (publ) | 115.61 Million SEK | -6157.136% |
| Swedencare AB (publ) | 484 Million SEK | -1394.628% |
| Toleranzia AB | -7.39 Million SEK | 97883.185% |
| Vivesto AB | -89.75 Million SEK | 8159.449% |